|
Neal I. Lindeman, M.D.
Assistant Professor of Pathology
Clinical Chemistry, Molecular Diagnostics
|
|
Academic Activities:
Genetic alterations in solid tumors, particularly involving growth factor signalling pathways in adenocarcinomas of the lung
|
Office
75 Francis Street
Al-2-217d Amory Building
Boston,MA
02115
Email1:
nilindeman@partners.org
|
Education and Training:
Medical School
1990
-
1994
:
University of Rochester
M.D.
|
Residency
1994
-
1998
:
UCSF
Anatomic & Clinical Pathology
|
Fellowship
1998
-
1999
:
UCSF
Surgical Pathology
|
Fellowship
1999
-
2000
:
Brigham and Women's Hospital
Molecular Genetic Pathology
|
Fellowship
2000
-
2003
:
Brigham and Women's Hospital
Research in Molecular Oncology
|
College
1986
-
1990
:
Williams College
BA, Chemistry
|
Clinical Specialties:
- Molecular Diagnostics
- Clinical Chemistry
- Pulmonary Pathology
- Anatomic Pathology
Research Interests:
- Genetic alteration
- Lung Cancer
- Mutation
- Cancer
- Signalling pathway
- Receptor
- Growth factor
- Targeted therapy
- Marker identification
- Mouse models
- Genome wide analysis
- Gene expression profiling
Publication:
- Lindeman N, Weidner N. Immunohistochemical profile of prostatic and urothelial carcinoma: impact of heat-induced epitope retrieval and presentation of tumors with intermediate features. Applied Immunohistochemistry. 1996;4(4):264-75.
- Lindeman N, Waltregny D, Signoretti S, Loda M. Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. Diagn Mol Pathol. 2002;11(4):187-92.
- Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-500.
- Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst. 2005;97(16):1185-94.
- Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, Laframboise T, Lee JC, Shah K, O'neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, Debiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med. 2006;12(7):852-855.
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316(5827):1039-43
- Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang M-C, Perera S, Zaghlul S, Borgman CL, Kubo S, Takahashi M, Sun Y, J, Chirieac LR, Padera R, Lindeman NI, Janne PA, Thomas RK, Meyerson M, Eck MJ, Engelman JA, Shapiro GI, Wong K-K. Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy. Cancer Cell 2007; 12(1):81-93.
- Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, Torrice C, Wu MC, Shimamura T, Perera S, Liang M-C, Cai D, Naumov GN, Bao L, Contreras C, Li D, Chen L, Krishnamurthy J, Koivunen J, Chirieac LR, Padera R, Bronson RT, Lindeman NI, Christiani DC, Lin X, Shapiro GI, Janne PA, Johnson B, Meyerson M, Kwiatkowski DJ, Castrillon DH, Bardessy N, Sharpless NE, Wong K-K. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448(7155):807-10.
- Barbara A. Weir1,2*, Michele S. Woo1*, Gad Getz2*, Sven Perner3,4, Li Ding5, Rameen Beroukhim1,2, William M. Lin1,2, Michael A. Province6, Aldi Kraja6, Laura A. Johnson3, Kinjal Shah1,2, Mitsuo Sato8, Roman K. Thomas1,2,9,10, Justine A. Barletta3, Ingrid B. Borecki6, Stephen Broderick11,12, Andrew C. Chang14, Derek Y. Chiang1,2, Lucian R. Chirieac3,16, Jeonghee Cho1, Yoshitaka Fujii17, Adi Gazdar8, Thomas Giordano15, Heidi Greulich1,2, Bruce E. Johnson1, Mark G. Kris11, Alex Lash11, Ling Lin5, Neal Lindeman3,16, Elaine R. Mardis5, John D. McPherson19, John Minna8, Margaret B. Morgan19, Mark Nadel1,2, Mark B. Orringer14, John R. Osborne5, Brad Ozenberger20, Alex H. Ramos1,2, James Robinson2, Jack A. Roth21, Valerie Rusch11, Hidefumi Sasaki17, Frances Shepherd25, Carrie Sougnez2, Margaret R. Spitz22, Ming-Sound Tsao25, David Twomey2, Roel Verhaak2, George M. Weinstock19, David A. Wheeler19, Wendy Winckler1,2, Akihiko Yoshizawa11, Soyoung Yu1, Maureen F. Zakowski11, Qunyuan Zhang6, David G. Beer14, Ignacio I. Wistuba23,24, Mark A. Watson7, Levi A. Garraway1,2, Marc Ladanyi11,12, William Travis11, William Pao11,12, Mark A. Rubin2,3, Stacey Gabriel2, Richard Gibbs19, Harold Varmus13, Richard K. Wilson5, Eric S. Lander2, 26, 27, & Matthew Meyerson.1,2, 16 Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, Dec 6;450(7171):893-8. Epub 2007 Nov 4.
- Lindeman N, Freeto S, Jarolim P. Immunosuppressant monitoring can be performed by UPLC – Tandem Mass Spectrometry in half the time needed for conventional HPLC - Tandem Mass Spectrometry, with comparable analytical performance. Clinica Chimica Acta 2008 Feb;388(1-2):207-10. Epub 2007 Oct 30.
- Sklar J, Lindeman N. Molecular diagnosis of cancer. In: Kelley’s Textbook of Internal Medicine, Humes HD, editor. Philadelphia (PA): Lippincott Williams & Wilkins;2000. p. 1815-24.
- Lindeman N, dal Cin P. Molecular testing for solid tumors. In: Essentials of Molecular Genetic Pathology, 1st edition, Cheng L, editor. Totowa (NJ): Humana Press;2008.
|
| < | Saturday, November 21, 2009 | > |
|
|